Cyclosporin A is a cyclic polypeptide composed of 11 amino acids, primarily known for its immunosuppressive properties. It is derived from the fungus Tolypocladium inflatum and is widely used in clinical settings to prevent organ transplant rejection and to treat autoimmune diseases. The structure of Cyclosporin A features a unique cyclic arrangement that contributes to its ability to inhibit T-cell activation by binding to cyclophilin, a cytosolic protein. This interaction disrupts the signaling pathways necessary for T-cell proliferation and cytokine production. Cyclosporin A is lipophilic, which influences its absorption and distribution in the body, and it is metabolized primarily by the liver through cytochrome P450 enzymes. Its pharmacokinetics can be affected by various factors, including drug interactions and individual patient characteristics. While effective, Cyclosporin A can also lead to side effects such as nephrotoxicity, hypertension, and increased risk of infections, necessitating careful monitoring during therapy. Overall, its unique chemical structure and mechanism of action make it a critical agent in immunosuppressive therapy.

Cyclosporin A, 6-[(2S,3R,4R)-10-(acetylamino)-3-hydroxy-4-methyl-2-(methylamino)decanoic acid]-8-(N-methyl-D-alanine)-

1383420-08-3: Cyclosporin A is a cyclic polypeptide composed of 11 amino acids, primarily known for its immunosuppressive properties. It is derived from the fungus Tolypocladium inflatum and is widely used in clinical settings to prevent organ transplant rejection and to treat autoimmune diseases. The structure of Cyclosporin A features a unique cyclic arrangement that contributes to its ability to inhibit T-cell activation by binding to cyclophilin, a cytosolic protein. This interaction disrupts the signaling pathways necessary for T-cell proliferation and cytokine production. Cyclosporin A is lipophilic, which influences its absorption and distribution in the body, and it is metabolized primarily by the liver through cytochrome P450 enzymes. Its pharmacokinetics can be affected by various factors, including drug interactions and individual patient characteristics. While effective, Cyclosporin A can also lead to side effects such as nephrotoxicity, hypertension, and increased risk of infections, necessitating careful monitoring during therapy. Overall, its unique chemical structure and mechanism of action make it a critical agent in immunosuppressive therapy.

<p>CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).</p>

CAS 1383420-08-3

Cyclosporin A, 6-[(2S,3R,4R)-10-(acetylamino)-3-hydroxy-4-methyl-2-(methylamino)decanoic acid]-8-(N-methyl-D-alanine)-

CRV431

Ref: TM-T70811